BioCatalystWatch
CGENWorkspace / CGEN / OverviewCompany library
Price
Market cap
Next catalystExpected 2H 2027Rilvegostomig — biliary tract cancer trials · Phase 3 dataCompany source ↗
Cash

Chart & Events

Candle interval

Core Clinical

COM701

PVRIG

PreINDP1P2P3FilingApproved
Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

COM701

PVRIG

PreINDP1P2P3FilingApproved
Upcoming / outlook

Other pipelines

COM701

PVRIG

PreINDP1P2P3FilingApproved
COM701

PVRIG

PreINDP1P2P3FilingApproved
COM701

PVRIG

COM701

PVRIG

COM701

PVRIG

PreINDP1P2P3FilingApproved
COM902

TIGIT

PreINDP1P2P3FilingApproved

Partner / License out

PD-1 × TIGIT

PreINDP1P2P3FilingApproved

PD-1 × TIGIT

PreINDP1P2P3FilingApproved
Upcoming / outlook

PD-1 × TIGIT

PD-1 × TIGIT

PD-1 × TIGIT

PD-1 × TIGIT

PD-1 × TIGIT

PreINDP1P2P3FilingApproved

IL-18BP

PreINDP1P2P3FilingApproved
COM902

TIGIT

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Company funding outlook

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

CGEN PR & News

CGEN SEC archive